药格局 YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
2026/01/06 – 2026/01/12
- New acceptances this week
- 461
- Drugs with new generic filings (by drug name, de-duplicated)
- 79
- Accepted this week, now under review
- 172
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Drug and company names link to detail pages; sign in to view them.
New acceptances this week
By application type and drug type
461filings, 117 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 175 |
| New drug | 134 |
| Generic | 117 |
| Import | 21 |
| Unspecified | 11 |
| Import re-registration | 3 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 284 |
| 治疗用生物制品 | 94 |
| TCM | 74 |
| 预防用生物制品 | 6 |
| Biologic | 3 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
79 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 非奈利酮片 | 5 | 3 | 71 |
| 2 | 磷酸奥司他韦胶囊 | 4 | 2 | 42 |
| 3 | 美阿沙坦钾片 | 4 | 2 | 33 |
| 4 | 布立西坦片 | 4 | 1 | 16 |
| 5 | 布瑞哌唑片 | 3 | 1 | 31 |
| 6 | 糠酸莫米松乳膏 | 3 | 1 | 16 |
| 7 | 左炔诺孕酮片 | 2 | 2 | 5 |
| 8 | 戊酸雌二醇片 | 2 | 2 | 7 |
| 9 | 瑞卢戈利片 | 2 | 2 | 2 |
| 10 | 艾托格列净片 | 2 | 2 | 11 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
261 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | 甘李药业山东有限公司 | 17 | 1 | 0 |
| 2 | 深圳信立泰药业股份有限公司 | 13 | 2 | 0 |
| 3 | Eli Lilly Nederland B.V. | 12 | 1 | 0 |
| 4 | 成都地奥集团天府药业股份有限公司 | 9 | 9 | 0 |
| 5 | 湖南九典诺纳医药科技有限公司 | 8 | 8 | 0 |
| 6 | 江苏豪森药业集团有限公司 | 7 | 4 | 0 |
| 7 | Bayer Vital GmbH | 7 | 3 | 0 |
| 8 | 浙江华海药业股份有限公司 | 7 | 3 | 7 |
| 9 | 华芢生物科技（青岛）股份有限公司 | 6 | 1 | 0 |
| 10 | 信达生物制药（苏州）有限公司 | 5 | 2 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
184 this week
154 more not listed (at most 30 rows).
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.